From "captive" agonism to insurmountable antagonism: Demonstrating the power of analytical pharmacology

Clinical and Experimental Pharmacology and Physiology

Volumn 28, Issue 3, 2001, Pages 223-229

  Christopoulos, Arthur ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer's disease; Analytical pharmacology; Captive agonism; Mathematical modelling; Musearinic receptors; Receptor theory; Xanomeline

Indexed keywords

ATROPINE; CHOLINERGIC RECEPTOR; CITRULLINE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR ANTAGONIST; XANOMELINE;

CALCIUM MOBILIZATION; CONFERENCE PAPER; DRUG DETERMINATION; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; MATHEMATICAL MODEL; QUANTITATIVE DIAGNOSIS; SYSTEM ANALYSIS;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; PHARMACOLOGY; RECEPTORS, DRUG;

EID: 0035123562     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2001.03376.x     Document Type: Conference Paper

References (35)

1. Bioassays: Past uses and future potential
2. The pharmacologic consequences of modeling synoptic receptor systems
3. Beyond eyeballing: Fitting models to experimental data
4. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain
5. 1 selective agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetarhydro-1-methylpyridines
6. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease
7. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease
8. 1 receptors
9. 1 muscarinic agonist
10. 1 receptors by xanomeline
11. 1 muscarinic acetylcholine receptor
12. Affinity and intrinsic activity in the theory of competitive inhibition
13. A modification of receptor theory
14. A personal view of pharmacology
15. Qualitative and quantitative assessment of relative agonist efficacy
16. 1 receptor by several muscarinic ligands
17. Pharmacological basis for functional selectivity of partial muscarinic receptor agonists
18. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum
19. 2-adrenoceptor agonists
20. Some quantitative uses of drug antagonists
21. Analysis of competitive agonist-antagonist interactions by nonlinear regression
22. Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusoff equations
23. 2-values by Schild-plot analysis and detection of allosteric interactions
24. 2 and affinity constants for pharamacological competitive antagonists be estimated?
25. 1 muscarinic acetylcholine receptor
26. The margin of safety of neuromuscular transmission
27. Pseudo-noncompetitive antagonism of musarinic receptor-mediated cyclic GMP formation and phosphoinositide hydrolysis by pirenzepine
28. Unsurmountable antagonism to 5hydroxytryptamine in rat kidney results from pseudoirreversible inhibition rather than multiple receptors or allosteric receptor modulation
29. 1-receptor blockers in the guinea pig papillary muscle
30. Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action
31. 2-adrenoceptor antagonists
32. The assessment of antagonist potency under conditions of transient response kinetics
33. The kinetics of action of acetylcholine antagonists in smooth muscle
34. Assessing the distribution of parameters in models of ligand-receptor interaction: To log or not to log